Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $62.25 Average PT from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $62.25.

Several brokerages have commented on CLDX. Citigroup began coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a "buy" rating and a $70.00 target price for the company. Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a report on Friday, September 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Wells Fargo & Company raised shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 26th. Finally, The Goldman Sachs Group started coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a "neutral" rating and a $45.00 price target for the company.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. KBC Group NV grew its position in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Celldex Therapeutics during the 2nd quarter worth about $76,000. Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 1st quarter worth about $147,000. CANADA LIFE ASSURANCE Co grew its position in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock worth $192,000 after buying an additional 955 shares during the period. Finally, Ameritas Investment Partners Inc. grew its position in shares of Celldex Therapeutics by 34.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company's stock valued at $260,000 after purchasing an additional 1,582 shares during the period.

Celldex Therapeutics Trading Down 0.9 %

Shares of CLDX traded down $0.25 during midday trading on Friday, hitting $26.22. The stock had a trading volume of 1,278,754 shares, compared to its average volume of 872,177. Celldex Therapeutics has a fifty-two week low of $24.43 and a fifty-two week high of $53.18. The business has a 50-day simple moving average of $33.60 and a two-hundred day simple moving average of $35.82. The firm has a market cap of $1.74 billion, a P/E ratio of -10.20 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 20.41%. The company had revenue of $3.19 million during the quarter, compared to analysts' expectations of $1.44 million. On average, analysts expect that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.